Achiko AG Announces Corporate Update Webcast
Commercial Delivery of its Saliva-Based Covid-19 Test AptameX™ Has Commenced...
Stay updated with breaking news from Dna Aptamer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Commercial Delivery of its Saliva-Based Covid-19 Test AptameX™ Has Commenced...
Achiko reports an EBITDA loss of USD $1.9 million, compared to an EBITDA loss of USD $4.6 million for the six months ending June 30, 2021.Focal points of...
ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces its...
Company Provides Novel Solution for Covid-19 Testing Gap with AptameX™, its Highly Effective and Low-Cost DNA Aptamer-Based Technology for the Detection of...
Achiko Establishes Joint Venture with PT Indonesia Farma Medis for Production and Distribution of its Test Platform for Covid-19 in Indonesia February 12, 2021 07:30 ET | Source: Achiko AG Achiko AG Zurich, SWITZERLAND Achiko Signs Agreement with PT Indonesia Farma Medis to Establish a New Joint Venture, including a Contract with PT Mitra Asa Pratama and a Memorandum of Understanding with PT Pharos Indonesia, Completion Subject to Formal Approvals Test Kits Will Be Integrated with Achiko’s Teman Sehat (Health Buddy) Mobile App to Address Growing ...